Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease

Journal of Neurology

Volumn 254, Issue SUPPL. 4, 2007, Pages

  Gordin, Ariel ^a   Brooks, David J ^b  

^a Hammersmith Hospital ^*  (Finland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Clinical studies; COMT inhibition; Entacapone; Parkinson's disease; Tolcapone

Indexed keywords

4 NITROCATECHOL; AMANTADINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DUODOPA; ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; ZALCITABINE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSKINESIA; EPIGASTRIC PAIN; FOLLOW UP; HALLUCINATION; HEMODYNAMICS; HUMAN; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; PAIN; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TIME; VOMITING;

EID: 34648815104     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-4007-9     Document Type: Conference Paper

References (78)

1. Assal F, Sphar L, Hadengue A, Rubia- Brandt A, Burkhard L, Rubia-Brandt L (1998) Tolcapone and fulminant hepatitis. Lancet 352:958
2. Axelrod J, Tomchick R (1958) Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 233:702-705
3. Birkmayer W, Hornykiewicz O (1961) Der L-3.4-dioxyphenylalanine (DOPA) Effekt bei der Parkinson Akinese. Wien Klin Wochenschr 73:787-788
4. Borgulya J, Brudere H, Bernauer K, Zurher G, Da Prada M (1989) Catechol-O-methyltransferase inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 72:952-968
5. Brooks DJ, Agid Y, Egger K, Widner H, Oestergard K, Holopainen A, and the TC-INIT Study Group (2005) Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53:197-203
6. Brooks DJ, Sagar H, and the UK-Irish Entacapone Study Group (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomised, placebo-controlled, double-blind sixmonth study. J Neurol Neurosurg Psychiatry 74:1064-1072
7. Carlsson A (2002) Treatment of Parkinson's disease with L-dopa. The early discovery phase, and comment on current problems. J Neural Transm 109:777-787
8. Chase TN, Baronti F, Fabbrini G, Hauser IJ, Juncos JL, Mouradian MM (1989) Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 39 (Suppl 2):7-10
9. Colosimo C (1999) The rise and fall of tolcapone. J Neurol 245:880-88
10. Cozias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 267:374-379
11. Durif F, Devaux I, Pere JJ, Delumeau J-C, Bordeix I, on behalf of the F-01 Study Group (2001) Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 45:111-118
12. Fenelon G, Gimenez-Roldan S, Montastruc J-L, Bermejo F, Durif F, Bordeix I, Pere JJ, Galiano L, Schadrack J (2003) Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized double-blind, multicentre study. J Neural Transm 110:239-251
13. Gershanik O, Emre M, Bernhard G, Sauer D (2003) Efficacy and safety of levodopa patients suboptimally controlled with levodopa in Parkinson's disease with levodopa alone, in daily clinical practice.An international, multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry 27:963-971
14. Gordin A, Kaakkola S, Teräväinen H (2003) Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 91:237-250
15. Gordin A, Kaakkola S, Teräväinen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111:1343-1363
16. Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A (2002) The effect of different repeated doses of entacapone on the pharmacokinetics of levodopa and on the clinical response to levodopa in Parkinson's disease. Clin Neuropharmacol 24:150-157
17. Heikkinen H, Varhe A, Lyly V, Korpela K, Laine T, Kaakkola S (2003) New levodopa, carbidopa and entacapone combination tablets. Eur J Neurol 10 (Suppl 1):P2141
18. Hornykiewicz O (2001) How L-dopa was discovered as a drug for Parkinson's disease 40 years ago. Wien Klin Wochenschr 113:855-862
19. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A (1994) COMT inhibition by high dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 11:582-588
20. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoprotanerol and epinephrine. Clin Pharmacol Ther 58:221-227
21. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1996a) Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 59:450-457
22. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A (1996b) Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine. Eur J Clin Pharmacol 51:273-276
23. Jenkinson D, Fizpatrick R, Peto V (1999) Health related quality of life measurement in patients with Parkinson's disease. Pharmaco Economics 15:157-165
24. Kaakkola S, Teräväinen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H, Gordin A (1995) Entacapone in combination with standard or controlled release levodopa-carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 2:1-7
25. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L, Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46:151-157
26. Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145-156
27. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D, and the SELECT-TC study group (2005) An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 112:221-230
28. Koller WC, Hutton JT, Tolosa E, Capilledio R and the carbidopa/levodopa study group (1999) Immediaterelease and controlled-release carbidopa/levodopa in PD: A five year randomised multicenter trial. Neurology 22:1012-1019
29. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, and the NOMESAFE Study Group (2003) Long-term efficacy and safety of entacapone in parkinsonian patients with motor fluctuations.An open study of 3 years duration. Eur J Neurol 10:137-146
30. Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO (2002) COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58:564-567
31. Linna M, Taimela E, Apajasalo M, Marttila R (2002) Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoeconomic Outcomes Res 2:91-97
32. Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H (2001) The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in Ldopa treated patients with Parkinson's disease. Clin Neuropharmacol 24:50-57
33. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1:345-349
34. Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10:54-56
35. Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66:317-323
36. Männistö PT, Kaakkola S, Nissinen E, Linden I-B, Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43:1465-1471
37. Männistö PT, Ulmanen I, Taskinen J, Kaakkola S (1994) Catechol-O-methyltransferase (COMT) and COMT inhibitors. In: Sandler M, Smith J, eds. Design of enzyme inhibitors as drugs. Oxford: Oxford University Press pp 625-647
38. Myllylä VV, Kultalahti E-R, Haapaniemi H, Leinonen M, and the Filomen Study Group (2001) Twelvemonth safety of entacapone in patients with Parkinson's disease. Eur J Neurol 28:53-60
39. Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H (2006) Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom study). Acta Neurol Scand 114:181-186
40. Nilsson D, Hansson LE, Johansson K, Nyström C, Paalzow L, Aquilonius SM (1998) Long term intraduodenal infusion of a water based levodopa carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 97:175-183
41. Nissinen E, Linden IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346:262-266
42. Novartis (2005) Novartis and Orion Pharma launch first Parkinson's disease study to explore potential of delaying motor complications with Stalevo. http://dominoext.novaeris.com/NC/NCM Media Rel 9798.nsf/0/ 35bb4edu0348176c1256f8000421bd9?
43. Nuijten JC, van Iperen P, Palmer C, van Hilten JB, Snyder E (2001) Cost-effectiviness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 4:316-328
44. Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535-540
45. Nutt JG (1998) Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 351:1221-1222
46. Nutt JG, Woodward WR, Beckner RM, Berggren K, Carter JH, Gancher ST, Hammerstad JT, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919
47. Nyholm D, Lennernaes H, Gomes-Trolin C, Aquilonius SM (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 25:89-96
48. Olanow CW, Stocchi F (2004) COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62 (Suppl 1):S72-S81
49. Paija O, Laine K, Kultalahti E-R, Leinonen M, Huupponen R, Gordin A, Reinikainen K (2005) Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 28:115-119
50. Palmer C, Nuijten JC, Schmier J, Subedi P, Snyder E (2002) Cost-effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmaco Economics 20:617-628
51. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Fehling C, Bell MA (1972) Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 286:8-14
52. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42:747-755
53. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure functioning and well being for individuals with Parkinson's disease. Qual Life Res 4:241-248
54. Peto V, Jenkinson C, Fitzpatrick R (2001) Determining minimally important difference for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 30:299-302
55. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68:589-594
56. Poewe W, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, and the Celomen Study Group (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-month randomised placebo-controlled, doubleblind study in Germany and Austria. Acta Neurol Scand 105:245-255
57. Poewe W, Deuschl G, Kultalahti E-R, Reinikainen K, Leinonen M (2003) Entacapone is safe in long-term use in Parkinson's disease. An Austrian-German open two-year study. Eur J Neurol 10 (Suppl 1):P3102
58. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, for the LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect of adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947-954
59. Reinikainen K, Karonen T, Haapaniemi H, Ahtinen H, Kaakkola S (2001) No indication for interactions between entacapone and antidepressants. Parkinsonism Related Disord 7 (Suppl 1):S67
60. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, and the Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309-1314
61. Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral entacapone after frequent multiple dosing and effects of levodopa disposition. Eur J Clin Pharmacol 55:461-467
62. Ruottinen HM, Rinne UK (1996a) Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222-233
63. Ruottinen HM, Rinne UK (1996b) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60:36-40
64. Ruottinen HM, Rinne UK (1996c) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19:283-296
65. Ruottinen HM, Rinne JO, Ruotsalainen UH, Bergman JR, Oikonen VJ, Haaparanta MT, Solin OH, Laihinen AO, Rinne UK (1995) Striatal (18F) fluoridopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Parkinson Dis Dementia Sect 10:91-106
66. Ruottinen HM, Niinivirta M, Bergman J, Oikonen VJ, Solin OH, Eskola O, Eronen E, Sonninen P, Rinne UK (2001) Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging. Synapse 40:19-26
67. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC (1988) Longterm duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24:87-89
68. Sawle GV, Burn DJ, Morrish PK, Larmmertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ (1994) The effect of entacapone (OR-611) on brain (18F)-6-L-fluorodopa metabolism: implications for levodopa therapy in Parkinson's disease. Neurology 44:1292-1297
69. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community based study. Brain 123:2297-2305
70. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N (1998) Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 13:885-894
71. Silver DE (2004) Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rew Neurotherapeutics 4:589-599
72. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamäki M, Olanow CW, Jenner P (2005) Multiple small doses of levodopa plus entacapone produces continuous dopaminergic stimulation and reduces dyskinesias induction in MPTP-treated drug naïve primates. Mov Disord 20:306-314
73. Syed N, Murphy J, Zimmerman T Jr, Mark HS, Sage JI (1998) Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13:336-338
74. Troconiz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO (1998) Population pharmacodynamic modelling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther 64:106-116
75. Waters C, Heikkinen H, Holopainen A, Leinonen M, Gordin A (2003) Entacapone is safe in long term use in patients with Parkinson's disease. A North American open 3-year safety and 1-year efficacy study. Eur J Neurol 10 (Suppl 1):P3105
76. Watkins P (2000) COMT inhibitors and liver toxicity. 55 (Suppl 4):S51-S52
77. Widner H (2003) Strategies to modify levodopa treatment. Adv Neurol 81:229-236
78. Zijlmans JCM, Debilly B, Rascol O, Lees AJ, Durif F (2004) Safety of entacapone and apomorphine co-administration in levodopa-treated Parkinson's disease patients; results of pharmacokinetics, pharmacodynamics, a multicenter, double-blind, placebo controlled, cross-over study. Mov Disord 17:1006-1011